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Abstract: 
Hypertension is a major public problem in the Kingdom of Saudi Arabia. Many ACE inhibitors are in clinical 
use as antihypertensive agents. However, theses ACE inhibitors possess many undesirable side effects. Recently, 
benzimidazole derivatives have been reported to possess ACE inhibitory activity. Therefore, it was aimed to 
provide some benzimidazole derivatives as ACE inhibitors with high potency and low toxicity. A series of some 
benzimidazole derivatives was designed as ACE inhibitor based on the literature. Molecular docking studies 
were carried out by using AutoDock vina software to identify the potent compounds. The compounds with 
predicted high potency were subjected for their toxicity prediction by osiris property calculator and the drug 
likeliness studies were carried out using available online softwares. The selected compounds were synthesized 
and evaluated for their ACE inhibitory activity using lisinopril as a standard drug. The compound 2-(2-
(butylthio)-5-methoxy-1H-indol-1-yl)-1-(2-nitrophenyl)ethan-1-one (17) was identified as an equipotent ACE 
inhibitor with respect to lisinopril. The in silico toxicity studies revealed that this compound was safe with 
respect to tumorogenecity, irritation effect, and reproductive effect. The application of the Lipinski’s Rule of 5 
and drug likeliness studies also revealed that this compound had an acceptable level of drug likeliness property 
with a potential to become a good orally active candidate. The in vitro ACE inhibitory assay of this compound 
also revealed that it was almost equipotent with respect to lisinopril. The compound (17) has required attributes 
to become a potential candidate as an ACE inhibitor. However, further studies are recommended to ensure its 
efficacy and safety in different animal models. 
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INTRODUCTION: 
Hypertension has become a leading cause of human 
morbidity and mortality. According to World 
Health Organization [1], about 40% of people aged 
25 and above are suffering from hypertension 
worldwide. According to recent studies [2, 3], the 
burden of hypertension is increasing at an alarming 
rate in Gulf region including in the Kingdom of 
Saudi Arabia. These studies have also stated that if 
the burden of hypertension remains uncontrolled, it 
will lead to major challenges to the health care 
system. Accordingly, efforts should be made to 
reduce the burden of hypertension worldwide.  
 
Angiotensin Converting Enzyme (ACE) [4] is an 
enzyme that converts Angiotensin I to Angiotensin 
II [4]. Angiotensin II is a potent vasoconstrictor 
and is implicated in the development of 
hypertension. Therefore, drugs that prevent the 
generation of Angiotensin II from Angiotensin I by 
inhibiting the Angiotensin Converting Enzyme 
(ACE) as well as the drugs that are Angiotensin II 
receptor antagonists are in clinical use as 
antihypertensive agents, for example, captopril [5], 
enalapril [6], lisinopril [7], telmisartan [8], 
candesartan [9], and azilsartan [10]. 
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However, many side effects are also associated 
with these drugs, for example, proteinurea, rashes, 
bad mouth odor, arrhythmia, allergic reactions, 
pancreatitis, alopecia, angioedema, and 
gastrointestinal disorders. Therefore, scientists are 
working to develop new ACE inhibitors as well as 
Angiotensine II receptor antagonists that are safer 
and effective than these existing drugs. 
Benzimidazole derivatives are reported to possess 
diverse biological activities [11,12]. Benzimidazole 
derivatives have also been reviewed as 
antihypertensive agents including as inhibitors of 
the Angiotensin Converting Enzyme (ACE) [13-
15]. Therefore, it was aimed to perform molecular 
modelling studies and to synthesize some 
benzimidazole derivatives as angiotensin 
converting enzyme inhibitors. 
 
MATERIALS AND METHODS: 
Molecular Docking Methodology 
Docking studies were carried out by using 
AutoDock Vina software [16], running on Linux 
Ubuntu 12.0, installed on Pentium i3 workstation. 
The program AutoDock Tools (ADT) released as an 
extension suite to the Python Molecular Viewer 
was used to prepare the protein and the ligand to 
convert the molecules into Autodock type, which is 
a prerequisite for the docking [17, 18]. Discovery 
studio 4 [19] was used for visualizing the 
resolutions of docked conformations. ChemDraw 
ultra 8.0 software [Chemical Structure Drawing 
Standard; Cambridge Soft corporation, USA 
(2003)] was used for construction of compounds 
which were transformed to 3D structures using 
Chem 3D ultra 8.0 software and the constructed 3D 
structures were energetically minimized by using 
MOPAC (semiempirical quantum mechanics) with 
the AM1 mozyme geometry, 100 iterations and 
minimum RMS gradient of 0.10. For each ligand, 
corresponding ATOM/HETATM and CONECT 
records were extracted from protein complex in the 
pdb file. After assigning bond orders, missing 
hydrogen atoms were added. Then in the AutoDock 
tools package, the partial atomic charges were 
calculated using Gasteiger-Marsili method [20] and 
after merging non-polar hydrogens, rotatable bonds 
were assigned. For receptor, the ligand, as well as 
any additional chains and all the heteroatoms 
including water molecules were removed. By the 
use of AutoDock Tools all missing hydrogens were 
added. Input molecule files for an AutoDock 
experiments must conform to the set of atom types 
supported by it. Therefore, pdbqt format was used 
to write ligands, recognized by AutoDock. The grid 
maps were calculated using AutoGrid [21]. In all 
dockings, a grid map with 60 x 60 x 60 points, a 
grid spacing of 0.503 A° were used, and the maps 
were centered on the ligand binding site. All the 
compounds taken under study were modeled by 
positioning them in the LPR (PDB ID: 1O86) 
binding site in the active domain of ACE protein as 
accorded by the published crystal structure. From 
the comparative docking study of our compounds 
with standard binding compound (LPR) we could 
observe how our compounds might bind to the 
ACE inhibition site, based on the knowledge of the 
structure of similar active sites. We redocked LPR 
into the active site of the protein and then we 
docked with our compounds in order to compare 
the binding affinity of both ligand and the test 
compounds. The docking score of the targeted 
compounds is also provided in Table 1. 
 
Table 1: Docking scores of the selected compounds and the physical constants of the synthesized 
compounds 
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Compound 
Number 
R Molecular Formula M.P. 
(±2oC) 
Yield 
(%) 
Rf Value Docking 
Score 
1 H C20H22N2O2S - - - -8.1 
2 4-Br C20H21BrN2O2S - - - -7.8 
3 3-Br C20H21BrN2O2S - - - -7.8 
4 2-Br C20H21BrN2O2S - - - -7.9 
5 2-Cl C20H21ClN2O2S - - - -8.1 
6 3-Cl C20H21ClN2O2S - - - -7.9 
7 4-Cl C20H21ClN2O2S - - - -7.7 
8 4-F C20H21FN2O2S - - - -8 
9 3-F C20H21FN2O2S - - - -8.1 
10 2-F C20H21FN2O2S 141 70 0.81 -8.3 
11 2-OCH3 C21H24N2O3S - - - -7.7 
12 3-OCH3 C21H24N2O3S - - - -7.9 
13 4-OCH3 C21H24N2O3S - - - -7.4 
14 4-CH3 C21H24N2O2S - - - -7.8 
15 3-CH3 C21H24N2O2S - - - -7.9 
16 2-CH3 C21H24N2O2S 147 60 0.83 -8.2 
17 2-NO2 C20H21N3O4S 155 55 0.88 -8.3 
18 3-NO2 C20H21N3O4S - - - -8.1 
19 4-NO2 C20H21N3O4S - - - -8.1 
Lisinopril - C21H31O5N3·2H2O - - - -8.3 
 
 
In Silico Drug Likeliness Studies 
To obtain the efficacious bioavailable drugs the 
successful compounds (10, 16, and 17) were 
subjected for the prediction of some basic 
pharmacokinetic properties such as Molecular 
weight, Lipophilicity, TPSA (total polar surface 
area), volume, Drug likeness, Hydrogen bond 
donors(HBD) and Hydrogen bond acceptors (HBA) 
etc. as shown in Table-1. An online molecular 
property prediction tool was used for this purpose 
found at www.molsoft.com.  
 
In Silico Toxicity Studies 
The compounds (10, 16, 1nd 17) were subjected for 
toxicity prediction by the osiris property calculator. 
Structure based drug design is now very routine 
work as many drugs fail to reach clinical phases 
because of ADME/TOX problems encountered. 
Therefore prediction of these problems before 
synthesis is a rational approach to minimize cost 
production of expensive chemicals. The Osiris 
calculations are tabulated in Table 2. Toxicity risks 
(mutagenicity, tumorogenicity, irritation, 
reproduction) and some physical properties of 
compounds (10-44) were calculated by Osiris 
methodology. 
 
Chemistry 
Melting points were recorded in open capillary 
tubes and are uncorrected. IR (KBr) spectra were 
recorded on a JASCO, FTIR-4100 
spectrophotometer. The 1H-NMR and 13C-NMR 
spectra were recorded on Bruker Ultrashield 500 
Plus MHz spectrophotometer. All reagents used in 
the present work were of analytical grade. The 
standard drug Lisinopril used for the assessment of 
in vitro ACE inhibitory activity was procured from 
Sigma Aldrich, USA. The purity of the compounds 
was checked on silica gel G plates using iodine 
vapours as visualizing agent. The Rf value of the 
compounds was determined by using a mixture of 
benzene and acetone (9:1). The synthetic pathway 
for the preparation of the benzimidazole derivatives 
is provided in Scheme 1. 
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Compound 10: R = 2-F
Compound 16: R = 2-CH3
Compound 17: R = 2-NO2
2-(butylsulfanyl)-5-methoxy-1H-benzimidazole
 
Synthesis of 2-(butylsulfanyl)-5-methoxy-1H-
benzimidazole 
5-methoxy-1H-benzimidazole-2-thiol (0.01 mol) 
and sodium hydroxide (0.01 mol) were mixed in 20 
ml of ethanol and the mixture was heated for 1 
hour. Butyl bromide (0.02 mol) was added to the 
mixture and the resulting mixture was refluxed for 
8 hours. The contents were reduced to half of its 
volume and then poured on crushed ice. The solid 
was filtered, washed with water and recrystallized 
from ethanol. 
 
General procedure for the synthesis of the 
targeted compounds 
2-(butylsulfanyl)-5-methoxy-1H-benzimidazole 
(0.01 mol) was dissolved in 25 ml of acetone. 
Potassium carbonate (0.015 mol) was added to the 
mixture and the mixture was stirred for about 30 
minutes. Appropriate phenacyl bromide (0.01 
mole) was added to the resulting mixture and it was 
stirred for 20 hours. The contents of the flask were 
reduced to half of its volume and it was poured on 
crushed ice. The solid separated was filtered, 
washed with water and recrystallized from ethanol. 
 
Angiotensin Converting Enzyme Inhibitory 
Assay 
The compounds (10, 16 and 17) that showed 
highest ACE inhibitory activity, according to the 
molecular modelling studies were subjected for the 
ACE inhibitory assay using Dojindo ACE Kit-
WST test kit, Dojindo Laboratories, Kumamoto, 
Japan [22]. The enzymatic reaction was initiated by 
the ACE and aminoacylase in the mixture 
containing 3HB-GGG (3-hydroxybutyrate 
glycylglycylglycine) and the ACE-inhibitor. The 
mixture was then incubated at 37oC for 60 minutes. 
During this incubation, the substrate, 3HB-GGG, 
was enzymatically cut into 3HB-G and G-G and 
then 3HB and G. The yield of 3HB was monitored 
indirectly through formazan concentration, which 
was measured at 450 nm after 10 minute reaction at 
25oC. Testing procedures were run according to the 
manufacturer’s instructions using a 96-well plate 
without modification, and the inhibition rate was 
calculated based on a comparison of the optical 
absorbance of samples-treated wells (𝐴𝑠), control 
wells (𝐴𝑐), and blank wells (𝐴𝑏). Absorbance was 
measured at 450 nm using the microplate reader 
Biotek-ELX800 (BioTek, Vermont, USA). 
Inhibition rates were calculated using the following 
equation. 
 
Inhibition rate (%) = [𝐴𝑐 – 𝐴𝑠 / 𝐴𝑐 − 𝐴𝑏] × 100 
 
Samples were suspected to inhibit the ACE 
activity, and therefore inhibit the formation of 
formazan. The more strongly inhibitory the activity 
of the samples, the less color appeared in the final 
solution. 
 
Statistical Analysis 
All ACE inhibitory activity data are presented as 
mean ± standard deviation (SD, n = 3). The data 
were analyzed by one-way analysis of variance 
(ANOVA) with Dunnett’s Multiple Comparison 
Test with respect to control group and standard 
groups using GraphPad Prism version 5.00 for 
Windows (GraphPad Software, San Diego 
California USA). The results were considered 
significantly different at p < 0.05. The IC50 values 
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were determined by linear regression calculator of 
GraphPad software. 
 
 
RESULTS: 
Molecular Docking Study 
The docking data of Lisinopril with the ACE 
protein revealed that the original co-crystallized 
and docked ligand overlapped with ACE protein 
elegantly, thereby validating our docking study. 
The results of docking scores in terms of binding 
affinity have been summarized in Table 1. The 
lisinopril exhibited binding affinity of -8.3 kcal/mol 
with the ACE protein and interacted with the Glu-
162, Asn-277, Asn-281, His-383 and Tyr-523 by 
forming conventional H-bond as shown in 2D-
diagram of ligand protein interaction (Figure 1). 
Interestingly, compounds 10 (Figure 2), 16 (Figure 
3), and 17 (Figure 4) also showed binding affinity 
close to Lisinopril. The compound 10 exhibited 
binding affinity of -8.3 kcal/mol; the compound 16 
exhibited binding affinity of -8.2 kcal/mol; and the 
compound 17 exhibited binding affinity of -8.3 
kcal/mol. 
 
 
 
Fig 1: 2D interaction of lisinopril with the active sites of the ACE 
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Fig 2: 2D interaction of compound 10 with the active sites of the ACE 
 
 
Fig 3: 2D interaction of compound 16 with the active sites of the ACE 
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Fig 4: 2D interaction of compound 17 with the active sites of the ACE 
 
In silico Drug Toxicity and Drug Likeliness 
Studies 
Hydrophilicity and Lipophilicity balance plays a 
very important role in the absorption or permeation 
of drugs into the systemic circulation. For this 
reason solubility and log P values were calculated 
and all the compounds under consideration were 
subjected to screen by Lipinski’s Rule of 5.  
 
It is evident from Table 2 that the compound 17 did 
not violate any Lipinski’s Rule. Therefore, 
compound 17 can be regarded as to be good oral 
candidates. Further the compounds were subjected 
for prediction of drug score and drug likeness along 
with the prediction of toxicity risk evaluation.  
 
Table 2: Pharmacokinetic Properties important for good oral bioavailability for the promising 
compounds 
 
Compound 
No. 
logP HBD HBA NRTB MW Drug 
likeness 
Lipinski’s 
violations 
Rule < 5 < 5 < 10 <10 <5 -- >/= 1 
10 5.15 0 4 8 372 0.42 1 
16 5.43 0 4 8 368 0.4 1 
17 4.94 0 7 9 399 -0.06 0 
NROTB, number of rotatable bonds; MW, molecular weight; LogP, logarithm of compound partition coefficient 
between n-octanol and water; HBA, number of hydrogen bond acceptors; HBD, number of hydrogen bond 
donors. 
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Table 3: Toxicity and Molecular properties Predicted by Osiris Calculator 
 
Cmpd 
No. 
Tumorigenic Mutagenic Irritation 
Reproductive 
Effect 
Vol TPSA Solubility DS 
10 
    
332 44.13 -4.53 0.47 
16 
    
343 44.13 -4.56 0.53 
17 
    
350 89.95 -4.68 0.32 
Colour of circle indicates level of toxicity; Green: low, Yellow: medium, Red: Highly toxic. 
TPSA, topological polar surface area; DS, Drug score. 
 
 
 
Fig 5: Drug likeness model score predicting graph 
 
The data of the Table 3 revealed that the selected 
compounds 10, 16, and 17 were safe with respect to 
Tumorogenecity, Irritation and reproductive effect.  
 
Drug Likeness can be defined as balance of various 
molecular properties and structure features which 
determine whether particular molecule is similar to 
the known drugs. Aptness of drug likeness can be 
judged by matching the graph of drug like 
compounds as shown in Figure 5. The compound 
17 further showed good level of drug likeness 
prediction. 
 
Chemistry 
The benzimidazole derivatives were prepared 
according to the method provided in Scheme 1. The 
compound 5-methoxy-1H-benzimidazole-2-thiol 
was reacted with carbon disulfide in the presence of 
potassium hydroxide to obtain 5-methoxy-1H-
benzimidazole-2-thiol. The 5-methoxy-1H-
benzimidazole-2-thiol was treated with butyl 
bromide in the presence of sodium hydroxide to 
provide 2-(butylsulfanyl)-5-methoxy-1H-
benzimidazole.. The 2-(butylsulfanyl)-5-methoxy-
1H-benzimidazole was treated with 2-
fluorophenacylbromide, 2-methylphenacylbromide, 
and 2-nitrophenacylbromide to obtain the targeted 
compounds 10, 16 and 17, respectively. The 
structure of the compound 17 was confirmed on the 
basis of following data. 
 
2-[2-(butylsulfanyl)-5-methoxy-1H-
benzimidazol-1-yl]-1-(2-nitrophenyl)ethanone 
(17): IR (KBr) cm-1: 2950, 1685 (C=O), 1335, 
1390; 1H-NMR (DMSO-d6, δ ppm): 0.88 (t, 3H), 
1.31-1.44 (m, 2H), 1.60-1.72 (m, 2H), 3.21 (t, 2H), 
3.88 (s, 3H), 5.97 (s, 2H), 7.15-7.41- (m, 3H), 7.53-
7.84 (m, 4H); 13C-NMR (DMSO-d6, δ ppm): 12.8, 
14.4, 21.6, 32.4, 36.4, 55.1, 55.8, 110.5, 112.1, 
121.8, 126.5 (2C), 133.0, 133.7, 134.4, 138.9, 
143.7, 151.6, 155.1, 163.1. 
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Table 4: In vitro ACE inhibitory activity of Compound 17 and the standard drug lisinopril 
Compound Concentration 
(μg/mL) 
%ACE Inhibition 
(Mean ± SD) 
IC50 
(μg/mL) 
Docking 
Score 
 
 
Lisinopril 
1 42.10 ± 0.10*  
0.86 
 
-8.3 2 59.99 ± 0.13* 
4 75.16 ± 0.16* 
8 87.11 ± 0.18* 
 
Compound 17 
1 41.98 ± 0.19*  
 
0.81 
 
 
-8.3 
2 60.12 ± 0.18* 
4 74.70 ± 0.22* 
8 85.06 ± 0.35* 
*p < 0.0001; n = 3. 
ACE inhibitory Assay 
Based on the molecular modelling results, In silico 
toxcicity data, and the drug likeliness prediction,  
the compound 17 was selected for further in vitro 
ACE inhibitory assay using Dojindo ACE Kit-
WST test kit, Dojindo Laboratories, Kumamoto, 
Japan. The ACE inhibitory activity data of these 
compounds are provided in Table 4. 
 
DISCUSSION: 
The compound 17 was identified as an equipotent 
ACE inhibitor with respect to standard drug 
lisinopril having a docking score of -8.3. The In 
Silico toxicity studies revealed that this compound 
was safe with respect to its tumorogenecity, 
irritation effect, and reproductive effect. The 
application of the Lipinski’s Rule of 5 and drug 
likeliness studies also revealed that this compound 
has an acceptable level of drug likeliness property 
with a potential to become a good orally active 
candidate. The in vitro ACE inhibitory assay of this 
compound also revealed that it was almost 
equipotent with respect to standard drug lisinopril. 
 
CONCLUSION: 
It is evident from the results that the compound 17 
has required attributes to become a potential 
candidate as an ACE inhibitor. However, further 
studies are recommended to ensure its efficacy and 
safety in different animal models. 
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